Jazz Pharmaceuticals Public Limited Company (JAZZ)

In the past six months, Jazz Pharmaceuticals' stock has seen significant movement. The stock had risen by 10.14% in the past month and 78.24% over the last year. Key events impacting the stock include strong Q1 2026 financial results with total revenues reaching $1.07 billion, FDA acceptance and priority review for Ziihera, full year and fourth quarter 2025 financial results with total revenues growing 5% in 2025, and constructive analyst sentiment.

The provided information does not explicitly detail demand seasonality for Jazz Pharmaceuticals' products and services. Analysts expect Jazz Pharmaceuticals' revenue to decline by 4.4% over the next 12 months, which suggests some anticipated demand challenges for its products and services. The company's strategy to diversify its portfolio, particularly with the growth in its oncology segment, aims to mitigate reliance on older neuroscience products that may face generic competition.

Jazz Pharmaceuticals Plc is a global biopharmaceutical company focused on developing and commercializing innovative medicines for serious diseases with limited therapeutic options, operating in the neuroscience and oncology sectors. Its neuroscience portfolio includes Xyrem, Xywav, Epidiolex, and Sunosi. Its oncology segment features Rylaze, Zepzelca, Vyxeos, Ziihera, Modeyso and Defitelio.

Jazz Pharmaceuticals has a commercial and operational footprint across North America, Europe, and Australia, and is expanding into Japan. The company partners with other companies to bring its medicines to patients globally, including in Asia Pacific and Latin America. It operates world-class facilities, including manufacturing centers, in the U.S., U.K., Ireland, and throughout Europe. Its medicines are available in nearly 100 countries.

Jazz Pharmaceuticals emphasizes its mission to improve patients' lives by developing and delivering life-changing therapies, particularly in areas with unmet medical needs. Advancements in oncology and neuroscience, a focus on rare diseases, and strong financial performance reflect positively on its reputation. The company has continued to advance its pipeline and expand its portfolio, with new product launches and progress in clinical trials.

Jazz Pharmaceuticals Plc is a publicly traded company with a significant portion of its stock held by institutional investors. Approximately 58.93% of the company's stock is owned by institutional investors, while insiders hold about 3.59%. Public companies and individual investors own approximately 37.49% of the stock. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., and Capital World Investors.